Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation. The company aims for **double-digit top-line growth**, despite recent muted growth (2% in FY26, 8% in FY25, 7% in FY24); the ambition remains **undiluted**.
From Glaxosmithkline Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation.
- Volumes have been growing at least in double-digits for the last two successive financial years for assets included in NLEM.
- GenMed business is expected to rebound to consistent 6-8% top-line growth after overcoming supply constraints.
- Vaccines portfolio is projected to grow in high double digits, driven by adult vaccines such as Shingrix and continued momentum in pediatric vaccines.
- Specialty portfolio, including oncology and new respiratory products, is scaling up with a focus on innovative, high-growth areas.
- 26 ongoing clinical trials in unmet medical needs signal pipeline-driven future growth.
- New launches in oncology (Blenrep, Zejula, Jemperli), respiratory, liver disease (Bepirovirsen and Efruxifermin), and vaccines (RSV vaccine) expected to drive growth.
- Freshness Index target: innovative portfolio to contribute ~10% of top-line, currently at 6%.
Profitability & Margins
See what Glaxosmithkline Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant launches planned in the next six months for the locally listed entity, including two in oncology and one adult vaccine, indicating ongoing investment in growth.
- Continuous investment focus on growing the business, with a preference to reinvest rather than prioritize EBITDA margin expansion.
- Emphasis on building innovative and specialty-led business segments (oncology, vaccines, respiratory), implying capital allocation towards these high-growth areas.
- Active work on cost optimization and digital initiatives (AI and IA) to enhance productivity and efficiency.
- Robust business continuity planning and alternative contingencies have been put in place to avoid supply issues, suggesting investments in supply chain resilience.
- Expansion in public accounts (CARE accounts) to increase access to proprietary medicines, likely requiring strategic investments in market access.
- Ongoing clinical trials (26 studies) and new compound developments (e.g., Velzatinib, B7-H4 antibody) demonstrate investment in R&D capabilities.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmithkline Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q4 FY26 results?
The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation. The company aims for **double-digit top-line growth**, despite recent muted growth (2% in FY26, 8% in FY25, 7% in FY24); the ambition remains **undiluted**.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 43.3 with a market cap of ₹45,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
Significant launches planned in the next six months for the locally listed entity, including two in oncology and one adult vaccine, indicating ongoing investment in growth.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.